Active GSK-3β Positive (%) | Active GSK-3β Negative (%) | Pvalue | |
---|---|---|---|
Total (n = 281) | 129 (46) | 152 (54) | |
Age (y) | |||
0-39 | 21 (46) | 25 (54) | 0.881 |
40-65 | 83 (47) | 94 (53) | |
66-99 | 25 (43) | 33 (57) | |
Gender | |||
Male | 94 (49) | 98 (51) | 0.157 |
Female | 35 (39) | 54 (61) | |
Locus | |||
Antrum | 63 (42) | 86 (58) | 0.230 |
Body and Cardia | 66 (50) | 66 (50) | |
WHO classification | |||
WD | 21 (78) | 6 (22) | < 0.001* |
MD | 42 (53) | 37 (47) | |
PD | 44 (37) | 74 (63) | |
Lauren's classification | |||
Intestinal | 63 (59) | 44 (41) | < 0.001* |
Diffuse | 62 (37) | 107 (63) | |
Mixed | 4 (80) | 1 (20) | |
TNM stage | |||
I | 53 (69) | 24 (31) | < 0.001* |
II | 60 (43) | 80 (57) | |
III | 16 (27) | 44 (73) | |
IV | 0 (0) | 4 (100) | |
Lymphatic invasion | |||
Absent | 104 (53) | 93 (47) | < 0.001* |
Present | 25 (30) | 59 (70) | |
Lymph node metastasis | |||
Absent | 63 (63) | 37 (37) | < 0.001* |
Present | 66 (36) | 115 (64) | |
Distant metastasis | |||
Absent | 124 (47) | 141 (53) | 0.304 |
Present | 5 (31) | 11 (69) |